



Dupilumab phase 2b study

Dupilumab phase 3 LIBERTY ASTHMA QUEST

Baseline blood eosinophils ≥ 150 cells/ μ L




Number of patients	0	2	4	8	12	16	20	24
Placebo ^a q2w	59	52	53	51	52	53	49	53
Dupilumab 200 mg q2w	58	57	58	51	51	52	53	53
Dupilumab 300 mg q2w	62	56	59	53	57	56	55	55




Number of patients	0	2	4	6	8	10	12	16	20	24	28	32	36	40	44	48	52
Matching placebo to dupilumab 200 mg q2w	105	100	96	97	97	99	102	98	96	96	90	90	93	91	90	89	74
Dupilumab 200 mg q2w	210	199	200	204	199	202	203	200	205	201	202	195	200	189	195	193	164
Matching placebo to dupilumab 300 mg q2w	107	100	101	103	103	101	102	103	101	100	100	100	98	98	94	93	78
Dupilumab 300 mg q2w	218	209	205	204	206	206	208	207	200	199	203	196	197	196	195	189	169

Baseline blood eosinophils ≥ 300 cells/ μ L




Number of patients	0	2	4	8	12	16	20	24
Placebo ^a q2w	33	27	27	26	27	28	26	28
Dupilumab 200 mg q2w	25	24	25	23	22	22	23	23
Dupilumab 300 mg q2w	29	25	27	24	26	25	24	24




Number of patients	0	2	4	6	8	10	12	16	20	24	28	32	36	40	44	48	52
Matching placebo to dupilumab 200 mg q2w	68	66	65	66	65	65	67	65	64	64	62	60	61	60	60	60	48
Dupilumab 200 mg q2w	134	126	127	133	129	129	130	128	132	129	129	127	128	122	127	124	104
Matching placebo to dupilumab 300 mg q2w	61	56	59	59	59	59	59	59	58	58	60	59	58	58	56	55	44
Dupilumab 300 mg q2w	129	122	118	120	119	120	122	121	115	115	116	113	115	113	113	107	93

Baseline FeNO ≥ 25 ppb




Number of patients	0	2	4	8	12	16	20	24
Placebo ^a q2w	40	34	37	34	35	35	33	36
Dupilumab 200 mg q2w	37	36	37	34	32	32	34	34
Dupilumab 300 mg q2w	37	34	36	32	33	33	32	33




Number of patients	0	2	4	6	8	10	12	16	20	24	28	32	36	40	44	48	52
Matching placebo to dupilumab 200 mg q2w	84	79	77	77	79	79	81	81	79	79	74	72	76	73	75	74	63
Dupilumab 200 mg q2w	153	147	146	150	146	148	147	146	151	147	147	141	146	139	142	139	114
Matching placebo to dupilumab 300 mg q2w	81	78	76	78	77	78	78	78	77	75	77	78	75	75	75	74	64
Dupilumab 300 mg q2w	147	139	138	136	139	137	139	139	139	135	133	136	136	134	134	133	128

Baseline blood eosinophils ≥ 150 cells/ μ L or FeNO ≥ 25 ppb



Number of patients	0	2	4	8	12	16	20	24
Placebo ^a q2w	66	58	60	57	58	59	54	59
Dupilumab 200 mg q2w	62	61	62	55	55	56	57	57
Dupilumab 300 mg q2w	65	59	62	56	60	59	58	58



Number of patients	0	2	4	6	8	10	12	16	20	24	28	32	36	40	44	48	52
Matching placebo to dupilumab 200 mg q2w	119	112	109	109	110	112	115	111	109	109	103	102	106	103	102	101	86
Dupilumab 200 mg q2w	237	226	226	230	225	227	229	228	231	227	226	219	225	213	220	217	183
Matching placebo to dupilumab 300 mg q2w	123	116	117	119	119	117	118	119	117	115	116	116	114	113	110	109	92
Dupilumab 300 mg q2w	241	232	228	227	229	228	231	230	221	220	225	218	219	217	216	209	189